

## **Accelaron Pharma Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 18-Feb-2014

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview.....	7
Company Profile.....	7
Product Portfolio Summary.....	8
Product Portfolio Drugs.....	13

[Return to Table of Contents](#)

# Acceleron Pharma Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Acceleron Pharma Inc
<b>Parent Company Name</b>	Acceleron Pharma Inc
<b>Website</b>	http://www.acceleronpharma.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	4
<b>Number of Inactive Drugs</b>	5
<b>Number of Patents as Owner</b>	40
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	8
<b>Key Indications</b>	Anemia,Beta thalassemia,Sickle cell anemia,Muscle weakness,Ovary tumor,Cancer,Diamond Blackfan anemia,Endometrioid carcinoma,Fallopian tube cancer,Hepatocellular carcinoma,Metastatic renal cancer,Myelofibrosis,Peritoneal tumor,Squamous cell carcinoma
<b>Key Target-based Actions</b>	TGF beta antagonist,Activin type-II receptor antagonist,GDF modulator,GDF-8 antagonist,Activin type-IIB receptor antagonist,Immunoglobulin gamma Fc receptor agonist,Alk-1 protein kinase inhibitor,Alk-3 protein kinase modulator,Bone morphogenetic protein-10 ligand modulator,Bone morphogenetic protein-9 ligand modulator,TGF beta ligand inhibitor,TNF
<b>Key Technologies</b>	Protein fusion,Biological therapeutic,Immunoglobulin-G,Antibody fragment,Subcutaneous formulation,Receptor fusion,Small molecule therapeutic,Protein chimeric,Soluble receptor,Antibody

## COMPANY PROFILE

### SUMMARY

Acceleron Pharma Inc, founded in 2003 and headquartered in Cambridge, MA, is a biopharmaceutical company developing novel protein therapeutics for cancer and rare diseases.

### COMPANY LOCATION

In May 2009, Acceleron signed a lease on a third facility in Cambridge, MA. At that time, the company planned to increase its workforce by 50% in 2009.

In June 2008, the company announced that it was to double the size of its facilities in Cambridge, MA and increase its workforce by 40% during 2008.

### LICENSING AGREEMENTS

In February 2008, as part of a codevelopment agreement for ACE-011, Acceleron and Celgene signed an option deal for the the development of three discovery programs in the field of osteoporosis and bone loss.

In August 2004, Artemis Pharmaceuticals GmbH and Acceleron signed a cooperation agreement in mouse genetics. Artemis would apply its ArteMice technology platforms to generate a specifically genetically engineered mouse model system for Acceleron, which would use the mouse model to develop drugs for the treatment of musculoskeletal and metabolic disorders.

### EARLY R&D

By May 2007, the company was investigating a number of research programs including ACE-05X for bone loss, ACE-06X and ACE-07X for fat accumulation, and ACE-08X and ACE-07X for muscle loss.

### FINANCIA

[Return to Table of Contents](#)



In January 2014, the company filed registration statement for a proposed public offering of common stock. Later that month, the company priced the offering of 2,400,000 shares of common stock at a price of \$50 per share. The underwriters were granted a 30-day option to buy up to an additional 360,000 shares of common stock. Later in January 2014, the offering closed, with full exercise of the underwriters' option. At that time, Acceleron had raised aggregate net proceeds of approximately \$129 million from the sale.

In December 2013, the company was selected for addition to the Russell 2000, Russell 3000 and Russell Global Indexes, and would join the indexes after the NASDAQ market closes on December 20, 2013.

In August 2013, Acceleron planned an IPO of its common stock. In September 2013, Acceleron priced its IPO of 5,580,000 shares of common stock at \$15.00 per share and granted the underwriters a 30-day option to purchase up to an additional 837,000 shares. Separately, in a concurrent, side-by-side private placement, Acceleron's collaboration partner, Celgene agreed to purchase 666,667 shares of common stock from Acceleron at the public offering price. Acceleron's stock has been approved for listing on the NASDAQ Global Market and was expected to begin trading under the ticker symbol "XLRN" on September 19, 2013. The IPO closed in September 2013. At that time, underwriters exercised in full option to purchase shares and the company raised gross proceeds of \$106.3 million. Net proceeds from the offering were \$96.7 million.

In December 2011, Acceleron raised \$30 million from a private financing.

In October 2007, the company raised \$31 million from a series C financing round. At that time, Acceleron planned to use the proceeds to advance its clinical and preclinical pipeline.

By August 2006, Acceleron had obtained \$30 million in Series B financing. In May 2007, investors included Advanced Technology Ventures, OrbiMed Advisors, Polaris Venture Partners, Sutter Hill Investors and Venrock Associates.

In January 2006, the company received \$8 million in debt financing from Hercules Technology Growth Capital.

In February 2004, Acceleron raised \$25 million in its first round of private equity financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)




## Drugs by Indication Table

Indication	Active	Inactive	Total
Musculoskeletal disease	1	6	7
Hematological disease	2	2	4
Genetic disorder	2	1	3
Metabolic disorder	0	2	2
Growth disorder	0	2	2
Immune disorder	0	2	2
Inflammatory disease	0	2	2
Neurological disease	1	1	2
Ocular disease	0	1	1
Injury	0	1	1
Nutritional disorder	0	1	1
Dermatological disease	1	0	1
Genitourinary disease	1	0	1
Neoplasm	1	0	1
Gynecology and obstetrics	1	0	1
Endocrine disease	1	0	1
Gastrointestinal disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	3
Discovery	1
Discontinued	1
No Development Reported	4

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	2	0	2
Drug - Funding	3	0	0	0	3
Drug - Development/Commercialization License	1	0	0	0	2
Technology - Delivery/Formulation	1	0	0	0	1

## CLINICAL TRIALS

[Return to Table of Contents](#)

## Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	4	8
Endocrine disease	1	6
Hematological disease	3	5
Musculoskeletal disease	0	5
Gynecology and obstetrics	1	4
Genitourinary disease	2	3
Degeneration	0	2
Neurological disease	0	2
Growth disorder	0	2
Gastrointestinal disease	2	2
Dermatological disease	1	1
Immune disorder	0	1
Genetic disorder	1	1

## Trials by Phase

Phase	Ongoing	All
Phase 2	7	11
Phase 1	0	6
Phase not specified	0	1

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	13	0	13
Endocrine disease	23	0	23

[Return to Table of Contents](#)



Gastrointestinal disease	14	0	14
Genitourinary disease	4	0	4
Growth disorder	13	0	13
Hematological disease	15	0	15
Degeneration	9	0	9
Andrology	1	0	1
Immune disorder	16	0	16
Psychiatric disorder	1	0	1
Musculoskeletal disease	30	0	30
Neoplasm	21	0	21
Ocular disease	3	0	3
Genetic disorder	2	0	2
Metabolic disorder	11	0	11
Mouth disease	1	0	1
Neurological disease	11	0	11
Nutritional disorder	11	0	11
Prophylaxis	1	0	1
Respiratory disease	4	0	4
Infectious disease	4	0	4
Injury	6	0	6
Toxicity and intoxication	1	0	1
Inflammatory disease	11	0	11
Gynecology and obstetrics	7	0	7
Dermatological disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### sotatercept

<b>Drug Name</b>	sotatercept
<b>Key Synonyms</b>	sotatercept
<b>Originator Company</b>	Acceleron Pharma Inc
<b>Active Companies</b>	Acceleron Pharma Inc, Celgene Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Myelofibrosis, Beta thalassemia, Anemia, Sickle cell anemia, Diamond Blackfan anemia
<b>Target-based Actions</b>	Activin type-II receptor antagonist
<b>Other Actions</b>	Synergist, Bone resorption inhibitor, Osteoblast modulator, Hematopoietic stimulant
<b>Technologies</b>	Antibody fragment, Immunoglobulin-G, Subcutaneous formulation, Biological therapeutic, Protein chimeric, Soluble receptor
<b>Last Change Date</b>	30-Jan-2014

### dalantercept

<b>Drug Name</b>	dalantercept
<b>Key Synonyms</b>	dalantercept
<b>Originator Company</b>	Acceleron Pharma Inc
<b>Active Companies</b>	Acceleron Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Peritoneal tumor, Squamous cell carcinoma, Fallopian tube cancer, Endometrioid carcinoma, Hepatocellular carcinoma, Ovary tumor, Metastatic renal cancer
<b>Target-based Actions</b>	Alk-1 protein kinase inhibitor, Bone morphogenetic protein-9 ligand modulator, TGF beta antagonist, Bone morphogenetic protein-10 ligand modulator
<b>Other Actions</b>	Anticancer, Ocular antineovascularisation agent, Angiogenesis inhibitor, Anticancer protein kinase inhibitor
<b>Technologies</b>	Antibody fragment, Receptor fusion, Subcutaneous formulation, Biological therapeutic, Protein chimeric, Protein fusion
<b>Last Change Date</b>	04-Dec-2013

[Return to Table of Contents](#)

## luspatercept

<b>Drug Name</b>	luspatercept
<b>Key Synonyms</b>	luspatercept
<b>Originator Company</b>	Accelaron Pharma Inc
<b>Active Companies</b>	Celgene Corp, Accelaron Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Beta thalassemia, Sickle cell anemia, Anemia
<b>Target-based Actions</b>	GDF modulator, TGF beta ligand inhibitor, TGF beta antagonist
<b>Other Actions</b>	Hematopoietic stimulant
<b>Technologies</b>	Antibody fragment, Receptor fusion, Immunoglobulin-G, Subcutaneous formulation, Biological therapeutic, Protein fusion, Soluble receptor
<b>Last Change Date</b>	03-Jan-2014

## ACE-083

<b>Drug Name</b>	ACE-083
<b>Key Synonyms</b>	
<b>Originator Company</b>	Accelaron Pharma Inc
<b>Active Companies</b>	Accelaron Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Muscle weakness
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	20-Dec-2013

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

